Adherence Enhancement for Renal Transplant Patients
Completed · Not applicable
Conditions studied: Renal Failure, Medication Adherence, Hypertension
In brief
Despite significant advances in the care of kidney transplant recipients, long term graft survival after renal transplantation remains suboptimal. Medication nonadherence and clinical inertia are key contributors to graft loss. The purpose of the proposed RCT feasibility study is to evaluate impact of a "bundled" wireless real time medication reminder system and blood pressure monitoring system in combination with a cognitive behavioral adherence skills enhancement program upon medication adherence, therapeutic drug concentration, and blood pressure, in nonadherent kidney transplant recipients with hypertension. We propose to recruit 60 kidney transplant recipients in phase 1 with 20 non-adherent continuing to phase 2 for a 5-month feasibility RCT.
Key facts
- Study ID
- NCT01859273
- Run by
- Medical University of South Carolina
- People needed
- 18
- Starts
- 2011-09-01
- Expected to finish
- 2013-08-01
- Last updated by the study team
- 2016-06-10
Who can join
Age: 21 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Persons > 21 years of age
- first time recipient of a solitary kidney transplant
- prescribed at least 3 medications for immunosuppression and hypertension
- previous history of non-adherence
- functioning kidney transplant
- ability to speak, hear and understand English
- able to use medication delivery device and self administer medications
- able to operate blood pressure monitor
- comfortable using cell phone
- no other diagnosis that might shorten lifespan
- transplant physician's assent that the patient can participate
You may not qualify if…
- failure to meet all inclusion criteria
Where it is running
- Medical University of South Carolina — Charleston, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.